Madrigal Pharma (MDGL) Tops Q2 EPS by 76c

Madrigal Pharma (NASDAQ: MDGL) reported Q2 EPS of ($1.99), $0.76 better than the analyst estimate of ($2.75). Revenue for the quarter came in at $364.3 million versus the consensus estimate of $349.15 million.

For earnings history and earnings-related data on Madrigal Pharma (MDGL) click here.

You May Also Be Interested In

• Concurrent Technologies (CNC:LN) PT Raised to GBP3.20 at Berenberg
• JPMorgan Reiterates Overweight Rating on Legrand SA (LR:FP) (LGRDY) and Places on Positive Catalyst Watch
• Geberit AG (GEBN:SW) (GBERY) PT Raised to CHF712 at Jefferies